The clinical performance is complex and often involves multiple systemic burdens. Early identification and standardized diagnosis are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in linking teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment plans. Treatment and management of systemic sclerosis requires individual development of treatment plans for skin types, typically including pharmacotherapy, rehabilitation interventions, regular follow-up, and more. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune diseases that have previously been difficult to treat have been significantly improved.
Treatment requires close monitoring of therapeutic efficacy and adverse reactions, adapting to timely regimens according to changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of systemic sclerosis-bounded skin types. The platform serves China International Medical Service System, a team of domestically authoritative experts in the field of autoimmune and rheumatic immunity, to provide the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.